Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey.
Department of Rheumatology, Uludag University School of Medicine, Bursa, Turkey.
Mod Rheumatol. 2024 Mar 28;34(3):584-591. doi: 10.1093/mr/road061.
The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS).
We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated.
There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05).
This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.
本研究旨在评估肥胖对强直性脊柱炎（AS）患者接受司库奇尤单抗治疗反应和药物生存率的影响。
我们进行了一项观察性队列研究，该研究基于土耳其（TURKBIO）登记处的生物药物数据库，纳入了 2018 年至 2021 年间的 AS 患者。患者被分为三组：正常体重（BMI<25kg/m2）、超重（BMI：25-30kg/m2）和肥胖（BMI≥30kg/m2）。在基线、3、6 和 12 个月时评估疾病活动度。还研究了 12 个月时的药物保留率。
共有 166 名使用司库奇尤单抗的 AS 患者（56.6%为男性，平均年龄：44.9±11.6 岁）。中位随访时间为 17.2（3-33.2）个月。48 名（28.9%）患者肥胖。肥胖组的平均年龄高于其他两组（P=0.003）。在 3、6 和 12 个月时，三组之间 50%的 Bath 强直性脊柱炎疾病活动指数（BASDAI50）、AS 国际协会 20 项（ASAS20）、ASAS40、强直性脊柱炎疾病活动评分（ASDAS）低疾病活动度和 ASDAS 临床重要改善反应没有统计学显著差异，尽管肥胖患者的数值较低。12 个月时，所有组的药物保留率相似（P>.05）。
本研究表明，肥胖并不影响 AS 患者接受司库奇尤单抗治疗反应和药物保留。
